<DOC>
	<DOCNO>NCT02380391</DOCNO>
	<brief_summary>Elevated on-treatment platelet reactivity independent risk factor major adverse cardiovascular event follow percutaneous coronary intervention ACS . People live HIV patient high risk recurrent event ACS people without HIV . The investigator hypothesize increase risk driven high platelet reactivity . Using nested case-control study design , HIV-infected HIV-uninfected patient first episode Acute Coronary Syndrome ( ACS ) treat percutaneous coronary intervention match age , sex , know diabetes mellitus anti-platelet therapy . The primary end-point residual platelet reactivity ( RPA ) dual antiplatelet therapy assess light transmission aggregometry ( LTA , 20µM ADP ) . The study conduct two large public university hospital central Paris , France .</brief_summary>
	<brief_title>EValuation REsidual Platelet REactivity After Acute Coronary Syndrome ( ST+/ST- ) HIV</brief_title>
	<detailed_description>Study design : Research routine care - hospital base , two site , nest case-control study , conduct Institute Cardiology within Pitie-Salpetriere University Hospital Cardiac Center Saint Antoine University Hospital . Number participant : Group 1 : n=80 HIV seropositive participant ( HIV+ ) Group 2 : n=160 HIV seronegative participant ( HIV- ) Sample size calculation base : 10 % absolute difference two group maximum platelet aggregation ( MPA ) residual platelet aggregation ( RPA ) ratio calculate MPA/RPA antiplatelet drug ( Aspirin , Clopidogrel , Prasugrel ) . Study justification : Platelet function risk marker independent ACS recurrence risk . People live HIV premature coronary artery disease , reveal ACS event , frequently experience ischemic recurrence people without HIV . Hypothesis : Due elevate residual platelet reactivity , people live HIV present frequent ACS recurrence follow first event people without HIV . Primary objective : Determine influence HIV antiretroviral medication platelet reactivity individual oral antiplatelet treatment . PLatelet reactivity assess one week 3 year initial acute coronary syndrome dual antiplatelet therapy . Methods : Platelet aggregation measure : 1 . Light transmission aggregometry ( LTA , 20µM adenosine diphosphate receptor inhibitor ( ADP ) 5µM arachidonic acid ( AA ) ) 2 . Point care VerifyNowRM P2Y12 ARU ( P2Y12 Reaction Units ARU Aspirin Reaction Units ) 3 . Flow cytometry ( VAsodilatator Simulated Phosphoprotein ( VASP ) )</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<criteria>INCLUSION CRITERIA : HIV+ group HIV1 seropositive , know minimum 6 month 18 year age old Hospitalisation acute coronary syndrome minimum one month prior inclusion ( without coronary revascularisation ) Under antiplatelet therapy Willing able give inform consent participate study HIV group HIV seronegative 18 year age old Hospitalisation acute coronary syndrome minimum one month prior inclusion ( without coronary revascularisation ) Under antiplatelet therapy Willing able give inform consent participate study EXCLUSION CRITERIA : Refusal give sign inform consent Presence counterindication nonindication antiplatelet therapy Not associate social security regime ( health insurance )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Platelet reactivity</keyword>
	<keyword>Acute coronary syndrome</keyword>
	<keyword>Antiplatelet treatment</keyword>
	<keyword>Antiretroviral treatment</keyword>
	<keyword>HIV</keyword>
</DOC>